Nicox reported 4.6 million in revenue in the first half of 2015 compared with 2.1 million in the same period of 2014, according to a press release. Net loss was reported at 15.8 million in the first half of the year compared with 16 million in the same…
Nicox reported 4.6 million in revenue in the first half of 2015 compared with 2.1 million in the same period of 2014, according to a press release. Net loss was reported at 15.8 million in the first half of the year compared with 16 million in the same…
The most demanding lens implant patient for me in regards to postoperative residual refractive error is the individual who has significant astigmatism and desires spectacle independent vision at all distances. While there are different surgeon preferences and lens implant approvals in each country, let’s presume we have access to and have chosen to use a bifocal or trifocal toric diffractive multifocal IOL.My experience is that in order to achieve high patient satisfaction, I need to generate a refractive outcome with no more than 0.5 D of residual astigmatism and less than 0.5 D of residual spherical equivalent. There are many published series of refractive outcomes, including those from the United Kingdom, the Swedish registry and, closer to home, a large registry of cases accumulated by Guy Kezirian. These data sets suggest that with standard methods of optical biometry, astigmatism measurement and steeper meridian marking, the “typical surgeon” only achieves this outcome in 50% to 65% of cases.
WASHINGTON–(BUSINESS WIRE)–Optica, The Optical Society’s newest journal, dedicated to rapidly disseminating the highest impact peer-reviewed research across the entire spectrum of optics and photonics, has celebrated its one-year anniversary. In its first year, Optica has established itself as a trusted source for some of the best and most exciting work in the optics and photonics field, demonstrated by 45% growth in article downloads in 2015 so far and 1 in 6 articles being featured in mains
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that Brian Levy, O.D., M.Sc., has joined Ocata’s Board of Directors. Most recently, Dr. Levy served as Chief Medical Officer of Aerie Pharmaceuticals, Inc. “Brian has been a widely regarded leader in the pharmaceutical industry for more than two decades, including fifteen years at Bausch + Lomb where he was the Chief Medical Officer and he brings sig
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Abbie Celniker, CEO of Eleven Biotherapeutics, will present at the NewsMakers in the Biotech Industry Conference ion Thursday, September 10, 2015 at 3:30 pm ET.